News Center

Home page

Peak Report

News reports

Announcement on Subsidiary Company Obtaining Drug Registration Certificate

Release time:

2021-05-20

Securities Code: 600668 Securities Abbreviation: Jianfeng Group No.: Lin 2020-023

Zhejiang Jianfeng Group Co., Ltd.

Announcement on Subsidiaries Obtaining Drug Registration Certificate

The Board of Directors and all directors of the Company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and assume individual and joint responsibility for the truthfulness, accuracy and completeness of its contents.

Important Content Note:

Obtaining the Drug Registration Certificate of esomeprazole sodium for injection this time indicates that Jianfeng Pharmaceutical is qualified to produce and sell the drug, which will further enrich Jianfeng Pharmaceutical's product line and help enhance the competitiveness of the company's pharmaceutical business.
Risk Warning: Because pharmaceutical products have the characteristics of high technology, high risk, and high added value, not only the pre-research and development of drugs, the period from approval to production is long, the investment is large, and there are many links, and the drug has obtained the registration The production and sales after the certificate are also easily affected by factors such as national policies and market environment. Investors are requested to pay attention to investment risks.

Recently, Zhejiang Jianfeng Pharmaceutical Co., Ltd. (hereinafter referred to as "the Company"), a holding subsidiary of Zhejiang Jianfeng Group Co., Ltd. (hereinafter referred to as "the Company"), received the Drug Registration Certificate of esomeprazole sodium for injection (Certificate No.: 2020S00572) approved and issued by the State Drug Administration. The relevant information is hereby announced as follows: basic Information of

1. Drugs
Drug Name: Esomeprazole Sodium for Injection
Dosage Form: Injection
Specification: 40mg (calculated by C ₁₇H ₁₉N ₃O ₃S)
Application Items: drug Registration (Domestic Production)
Registration Classification: Original Chemical Drug Category 6
Applicant: Zhejiang Jianfeng Pharmaceutical Co., Ltd.
acceptance number: CYHS1301863 Zhejiang
Certificate No.: 2020S00572
Drug Registration Standard No.: YBH03162020
Drug Validity Period: 12 Months
Drug Approval Number: the validity period of the drug approval document number of the national drug standard H20203449
is until August 25, 2025
approval conclusion: according to the the People's Republic of China drug administration law and relevant regulations, after examination, this product meets the relevant requirements for drug registration, is approved for registration, and a drug registration certificate is issued. The production process, quality standards, instructions and labels shall be in accordance with the attached.

2. Drug Development and Related Conditions
This product is used to treat:
1. as an alternative therapy for GERD when oral therapy is not applicable.
2. Use in low-risk patients with acute gastric or duodenal ulcer bleeding for whom oral therapy is not applicable (gastroscopic Forrest grading IIc-III).
Esomeprazole sodium for injection has been listed in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug List (2017 Edition)" and classified as Class B; it is not included in the "National Essential Drugs List (2018 Edition)". At present, 30 enterprises, including AstraZeneca Pharmaceutical Co., Ltd., Zhengda Tianqing Pharmaceutical Group Co., Ltd., Qilu Pharmaceutical Co., Ltd., and Shandong Luoxin Pharmaceutical Group Co., Ltd., have been approved for listing in China. According to the data of the intranet, the domestic sales in 2019 (including urban and county-level public hospitals, community and township health centers) are about 3.317 billion yuan.
Peak Pharmaceutical submitted an application for registration of the drug to the State Food and Drug Administration on November 28, 2013 and was accepted. Up to now, the research and development investment of esomeprazole sodium for injection project of Jianfeng Pharmaceutical Co., Ltd. is about 14.9128 million yuan. The impact of

3. on the company and its risks suggest that
Jianfeng Pharmaceutical already has a corresponding production line. The acquisition of the Drug Registration Certificate of esomeprazole sodium for injection this time indicates that Jianfeng Pharmaceutical has the qualification to produce and sell the drug, which will further enrich the product line of Jianfeng Pharmaceutical and help to enhance the competitiveness of the company's pharmaceutical business. Due to the characteristics of high technology, high risk and high added value of pharmaceutical products, not only the period from the preliminary research and development, approval to production is long, the investment is large and there are many links, but also the production and sales of drugs after obtaining the registration certificate are easily affected by national policies, market environment and other factors. Please pay attention to the investment risk.

This is to announce

Zhejiang Jianfeng Group Co., Ltd.

Board of Directors
September 5, 2020

More information

Chairman Jiang Xiaomeng was named "Fengyun Zhejiang Merchants"

On the evening of January 13, the 2021 "Fengyun Zhejiang Merchants" award ceremony was held in Hangzhou. Ten outstanding Zhejiang businessmen, including Jiang Xiaomeng, chairman of the group company, won the honor. The annual "Fengyun Zhejiang Merchants" selection activity is guided by the Propaganda Department of the Zhejiang Provincial Committee of the Communist Party of China, sponsored by Zhejiang Radio and Television Group, and co-organized by Zhejiang Economic Television, Qianjiang Evening News and Zhejiang Merchants Magazine. Provincial Department of Economics and Information Technology, Provincial Department of Science and Technology, Provincial Department of Commerce, Provincial Federation of Industry and Commerce and many other units jointly co-organized. Since its establishment in 2003, it has been held for 18 sessions, and more than 180 "Fengyun Zhejiang businessmen" have been selected. They are all successful models and fresh samples of Zhejiang's economic development.

2022

01-17

Peak re-listed China's top 100 building materials enterprises

China Building Materials Enterprise Management Association recently released a series of lists of "2021 Top 500 Chinese Building Materials Enterprises", and Jianfeng Group ranked among the "2021 Top 100 Chinese Building Materials Enterprises". This series of lists has been released every year since 2002, and has received extensive attention and active participation from governments at all levels, building materials authorities and building materials companies. It has become a vane of China's building materials industry. Since participating in the selection of the list, the peak has been ranked among the top 100 building materials enterprises in China for many years.

2022

01-04

Hubei "Wisdom and Energy Saving" Focus on Daye Peak

On the morning of December 3, more than 180 people from relevant competent departments at all levels and key energy consuming units in Hubei Province gathered in Daye Jianfeng cement company to visit and understand Daye Jianfeng's practice and experience in intelligent energy conservation. On the same day, the provincial smart energy-saving training meeting organized by the Hubei Provincial Development and Reform Commission was held in daye city. daye peak was the only visiting enterprise arranged for the meeting.

2021

12-13

Daye Peak passed the intellectual property management system certification.

Recently, Daye Jianfeng Cement Company received the intellectual property management system certification certificate issued by Guozhi (Beijing) Certification Company. This is also the first system certificate obtained by the company to implement the intellectual property management standard certification. In recent years, Daye Jianfeng has actively mobilized employees to carry out technological innovation, invention and creation, and timely summarized technological achievements and filed patents. Up to now, it has obtained 31 invention patents and utility model patents. At the same time, Daye's concept of the creation, application, management and protection of intellectual property rights is also increasing, and it continues to increase the promotion of new products and new technologies with high value-added intellectual property rights, and enhance the value of corporate intangible assets. Intensity. The passing of this system certification can not only obtain government incentives and funding, but also the basic conditions for intellectual property work and the prerequisite for applying for related projects.

2021

12-13

The Group Party Committee organized the Sixth Plenary Session of the 19th Central Committee to preach the spirit.

In order to quickly set off an upsurge of studying and implementing the spirit of the Sixth Plenary Session of the 19th Central Committee of the Party, and effectively unify thoughts and actions into the decision-making and deployment of the Party Central Committee with Comrade Xi Jinping as the core, and earnestly learn in the depths, seek new places, and do In practice, on December 1, the party committee of the group company held a spiritual lecture at the Sixth Plenary Session of the 19th Central Committee, which was delivered by Jiang Xiaomeng.

2021

12-13

Group Party Committee to Learn the Spirit of the Sixth Plenary Session of the 19th Central Committee

On the afternoon of November 18, the Party Committee of the Group held a special meeting to learn the spirit of the Sixth Plenary Session of the 19th CPC Central Committee and make arrangements for in-depth study. The Sixth Plenary Session of the 19th Central Committee of the Communist Party of China is an important meeting of overall and historical significance held at the historical intersection of the "two centenary" goals on the occasion of celebrating the centenary of the Communist Party of China. The "Resolution of the Central Committee of the Communist Party of China on the Major Achievements and Historical Experience of the Party's Hundred Years of Struggle" approved by the plenary session is a Marxist programmatic document that inherits the past and the future. It is also an action guide to learn from history, create the future, and realize the great rejuvenation of the Chinese nation. At the special meeting, Jiang Xiaomeng, Secretary of the Party committee of the group, and all the members of the Party committee, from the great achievements, historical significance and historical experience created by the party's 100 year history, since the 18th National Congress of the Communist Party of China, it has adhered to the party's overall leadership, comprehensive and strict governance of the party, economic construction, comprehensive deepening of reform and opening up, political construction, comprehensive rule of law, cultural construction, social construction, ecological civilization construction, national defense and military construction, and maintenance of national security., Adhere to the "one country, two systems" and promote the reunification of the motherland, diplomatic work and other 13 important achievements, comprehensively interpret and study the resolutions of the plenary session.

2021

11-22

< 1...7 8 9...61 > 跳转到页